Can a new injection tame Gout's uric acid?
NCT ID NCT07752810
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This study tests an investigational drug called HZBio1 in people with gout. The goal is to see if it is safe and how well it lowers uric acid levels. Participants receive multiple injections of HZBio1 over several weeks. The trial includes adults aged 18 to 70 with gout and elevated uric acid.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HZBio1, an investigational drug given by injection
- What this could lead to
- If successful, HZBio1 could offer a new treatment option to help control uric acid levels and reduce gout flares.
- What could go wrong
- This is an early-stage trial, so the drug may not work as hoped or may cause side effects. More research will be needed before it could become available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an ancient herbal formula tame gout?
- New drug combo aims to tame stubborn gout flares
- Timing matters: study tests if starting gout drug during a flare is safe
- Ultrasound may solve arthritis diagnosis puzzle
- Probiotic supplement shows promise for gout prevention in small study
- New gout drug dotinurad shows promise in early trial